Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals (NASDAQ: TTPH) is a publicly-traded, clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase’s lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy. Tetraphase has created more than 3,000 novel tetracycline analogs using its technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability.

In 2013, Tetraphase raised a $45M IPO and began trading under the ticker “TTPH.”


Company Profile

Tetraphase Pharmaceuticals Logo

Flagship Partners:

  • Doug Cole, Managing Partner